Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing ...

Merck (NYSE:MRK) on Thursday announced plans to invest $895M to expand a manufacturing facility in Kansas, becoming the ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

Roche warned that President Trump's executive order on drug pricing threatens its planned $50 billion investment in the ...

A new manufacturing plant in De Soto will be a Center of Excellence for the global company, along with expanded R&D ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Rahway, New Jersey Friday, May 9, 2025, 09:00 Hrs [IST] ...

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

Merck will have early-stage opportunities to help startups set up for future success in the pharmaceutical and life sciences fields.

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

The investment comprising $860M allotted for the site's existing production facility and $35M allocated for R&D labs is set to boost the production capacity of Merck Animal Health’s large ...